Former President Joe Biden diagnosed with ‘aggressive’ form of prostate cancer

Former President Joe Biden diagnosed with ‘aggressive’ form of prostate cancer


Former President Joe Biden speaks during the Advocates, Counselors, and Representatives for the Disabled bipartisan conference at the Sofitel Chicago Magnificent Mile on Tuesday, April 15, 2025.

Eileen T. Meslar | Chicago Tribune | Getty Images

Former President Joe Biden has been diagnosed with prostate cancer, his office said Sunday.

Biden was seen last week by doctors after urinary symptoms and a prostate nodule was found. He was diagnosed with prostate cancer on Friday, with the cancer cells having spread to the bone. His office said he has stage 9 cancer.

“While this represents a more aggressive form of the disease, the cancer appears to be hormone-sensitive which allows for effective management,” his office said. “The President and his family are reviewing treatment options with his physicians.”

Prostate cancers are given a score called a Gleason score that measures, on a scale of 1 to 10, how the cancerous cells look compared with normal cells. Biden’s score of 9 suggests his cancer is among the most aggressive.

When prostate cancer spreads to other parts of the body, it often spreads to the bones. Metastasized cancer is much harder to treat than localized cancer because it can be hard for drugs to reach all the tumors and completely root out the disease.

However, when prostate cancers need hormones to grow, as in Biden’s case, they can be susceptible to treatment that deprives the tumors of hormones.

The health of Biden, 82, was a dominant concern among voters during his time as president. After a calamitous debate performance in June while seeking reelection, Biden abandoned his bid for a second term. Then-Vice President Kamala Harris became the nominee and lost to Republican Donald Trump, who returned to the White House after a four-year hiatus.

But in recent days, Biden rejected concerns about his age despite reporting in the new book “Original Sin” by Jake Tapper and Alex Thompson that aides had shielded the public from the extent of his decline while serving as president.

In February 2023, Biden had a skin lesion removed from his chest that was a basal cell carcinoma, a common form of skin cancer. And in November 2021, he had a polyp removed from his colon that was a benign, but potentially pre-cancerous lesion.

In 2022, Biden made a “cancer moonshot” one of his administration’s priorities with the goal of halving the cancer death rate over the next 25 years. The initiative was a continuation of his work as vice president to address a disease that had killed his older son, Beau.



Source

Pinterest stock falls 10% after earnings miss
World

Pinterest stock falls 10% after earnings miss

Bill Ready, CEO of Pinterest, speaks at the 28th annual Milken Institute Global Conference at the Beverly Hilton in Beverly Hills, California, on May 5, 2025. Patrick T. Fallon | AFP | Getty Images Pinterest shares were down more than 10% on Thursday after the company reported second-quarter earnings that missed on earnings per share. […]

Read More
Doximity buys Pathway Medical for  million to help doctors get AI-powered answers
World

Doximity buys Pathway Medical for $63 million to help doctors get AI-powered answers

Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021. Source: NYSE Doximity is diving deeper into artificial intelligence, announcing on Thursday the acquisition of startup Pathway Medical for $63 million.  Pathway has built an AI-powered clinical reference tool that doctors can use to ask questions about guidelines, drugs […]

Read More
Buy the dip on this ‘pure play automation’ stock, says Bank of America
World

Buy the dip on this ‘pure play automation’ stock, says Bank of America

Bank of America is sticking by Emerson Electric after a postearnings sell-off, as the company could benefit from manufacturing shifting back to the U.S. Emerson Electric’s fiscal third-quarter results were mixed, hurt by weaker-than-expected sales. The company, which makes autonomous technology and industrial goods, lowered its full-year outlook and now estimates sales will rise 3.5% […]

Read More